UBS: Top 3 Euro Pharma & Biotech Picks for 2026

UBS Highlights Key Pharma Growth Stocks

UBS has identified Genmab, UCB, and Zealand Pharma as top Buy-rated European pharmaceutical and biotech companies positioned for growth in 2026. The investment bank highlights that critical upcoming clinical trials and new product developments are set to drive performance for these selected firms.

Sector Outlook and Key Catalysts

According to the bank's analysis, many companies in the sector face pivotal Phase 3 trial readouts that could materially reshape valuations. Genmab's trials are crucial for addressing its 2029 patent cliff. UCB's Bimzelx trial could accelerate its expansion into rheumatology, while Zealand Pharma's obesity drug trials show significant promise.

Potential Market Impact

A successful outcome in these trials could significantly boost the equity stories for each company. For Genmab, positive results from two of its three key assets could match peak operating profit from its expiring Darzalex royalties. UCB could see upgraded peak sales forecasts, and Zealand Pharma could capture a larger share of the obesity treatment market.

Summary and Outlook

While UBS warns that stocks in the sector could be volatile given the nature of ongoing trials, these three companies are fundamentally well-positioned. Investors should closely monitor the clinical data readouts scheduled for 2026, as they represent major inflection points for valuation.

FAQ

Q: Which companies did UBS identify as top European pharma picks?
A: UBS's top picks are Genmab, UCB, and Zealand Pharma.

Q: What are the primary growth drivers for these stocks?
A: The key growth drivers are upcoming Phase 3 clinical trial results and strategic product developments.

Source: Investing.com